Investigational drug · Phase 2
Tominersen
Also called: RO7234292, RG6042
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Huntington Disease.
Phase 2Last checked: Nov 19, 2026Latest source record: Aug 10, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
5
Any phase or sponsor naming "Tominersen"
First trial start
2023
Feb 3, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Tominersen", any sponsor or status.
Conditions studied
As listed on its trial records.
- Huntington Disease
Approved drugs for the same conditions: Huntington's disease chorea · Neurology
Largest trials
Live from ClinicalTrials.gov: studies naming "Tominersen" as an intervention, largest first.
- A Study to Evaluate the Efficacy and Safety of Intrathecally Administered RO7234292 (RG6042) in Participants With Manifest Huntington's DiseasePivotal-lookingCompleted
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT03761849 · 899 participants · Start Jan 23, 2019 · Primary completion Mar 24, 2022
Drug: RO7234292; Placebo · For: Huntingtons Disease
Sites: Birmingham, Alabama; Phoenix, Arizona; La Jolla, California · 96 sites in all
- GENERATION HD2. A Study to Evaluate the Safety, Biomarkers, and Efficacy of Tominersen Compared With Placebo in Participants With Prodromal and Early Manifest Huntington's DiseasePivotal-lookingActive, not recruiting
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT05686551 · 301 participants · Start Feb 3, 2023 · Primary completion May 14, 2026
Drug: Tominersen; Placebo · For: Huntington Disease
Sites: Birmingham, Alabama; Phoenix, Arizona; Sacramento, California · 70 sites in all
- An Open-Label Extension Study to Evaluate Long-Term Safety and Tolerability of RO7234292 (RG6042) in Huntington's Disease Participants Who Participated in Prior Roche and Genentech Sponsored StudiesPivotal-lookingCompleted
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT03842969 · 236 participants · Start Apr 23, 2019 · Primary completion Mar 25, 2022
Drug: RO7234292 (RG6042) · For: Huntington Disease
Sites: Birmingham, Alabama; La Jolla, California; Palo Alto, California · 38 sites in all
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT03342053 · 46 participants · Start Jan 2, 2018 · Primary completion Oct 8, 2019
Drug: RO7234292 (RG6042) · For: Huntington's Disease
Sites: Vancouver, Canada; Berlin, Germany; Bochum, Germany · 9 sites in all
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT04000594 · 12 participants · Start Sep 2, 2019 · Primary completion Jan 18, 2022
Drug: RO7234292 (RG6042) · For: Huntingtons Disease
Sites: Leiden, Netherlands; London, United Kingdom; Manchester, United Kingdom
Newest research
PubMed records naming it or its code names, newest first.
- Huntington's disease clinical trials update: August 2026.
Farag M, Kinyomi O, Tabrizi SJ, et al. · J Huntingtons Dis 2026
- Toward a Platform PBPK Model to Characterize the Plasma and Tissue Disposition of Unconjugated Antisense Oligonucleotides and GalNAc-Conjugated Small Interfering RNAs in Preclinical Species and Human.
Desai DA, Cristofoletti R · Clin Pharmacol Ther 2026
- A Cost-Effectiveness Analysis for Treatments of Patients with Early Stage Huntington's Disease in the USA.
Patil D, Slejko JF, Savitt JM, et al. · Pharmacoecon Open 2026
- Half-Life as a Therapeutic Design Axis: Targeting Short-Lived lncRNAs With Antisense Oligonucleotides.
Tani H · IUBMB Life 2026
- Quantitative relationship between tominersen concentrations in cerebrospinal fluid and biomarker changes in Huntington's disease patients.
Yamamoto Y, Silber Baumann HE, Björnsson M, et al. · Br J Clin Pharmacol 2026
- Gene therapy for huntington's disease: advances, challenges, and future perspectives.
Kaushal R, Yadav M, Kosey S, et al. · Neurogenetics 2026
Also in development for Huntington Disease
- SKY-0515Phase 33 trials
Skyhawk Therapeutics, Inc. · Huntington Disease, Huntingtons Disease, Huntington's Disease (HD)
- PridopidinePhase 32 trials
Prilenia · Amyotrophic Lateral Sclerosis, Huntington Disease
- ER2001Phase 21 trial
ExoRNA Bioscience · Huntington Disease
- MBF-015Phase 21 trial
Medibiofarma S.L. · Huntington Disease
- VO659Phase 21 trial
Vico Therapeutics B. V. · Spinocerebellar Ataxia Type 1, Spinocerebellar Ataxia Type 3, Huntington Disease
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Roche (Genentech).
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.